LAUSR

A 53-year-old man presented with an erythematous papular skin eruption. Ten days prior to the appearance of the lesions, he had received the second dose of the coronavirus disease 2019 (COVID19) vaccine (ChAdOx1 nCoV-19 [AstraZeneca]). He denied taking any medication or supplements within 2 months before and after the second vaccination. He also denied history of any other contact or exposure. After the first injection of the COVID-19 vaccine, no adverse events occurred. Physical examination showed well-demarcated erythematous macular patches distributed symmetrically over the axillary and inguinal areas, with skin desquamation and swelling in the scrotal area and on the glans penis (Figure 1A-C). Systemic signs were absent. The blood test results were normal. Findings of direct microscopy with 10% potassium hydroxide (KOH) and wound culture were negative. The patient refused to undergo a skin biopsy. Based on these findings and the patient's history, we considered symmetric drugrelated intertriginous and flexural exanthema (SDRIFE)–like eruption. Methylprednisolone 30 mg/day was administered for 1 week, and the dose was tapered to 15 mg/day for another week with topical corticosteroid cream. After 2 weeks, his condition resolved.